LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) (USD $)	12 Months Ended			1 Months Ended			3 Months Ended	12 Months Ended					1 Months Ended							3 Months Ended		11 Months Ended	1 Months Ended		3 Months Ended	12 Months Ended		1 Months Ended		12 Months Ended				1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2011 Abbott Products Inc.	Jan. 31, 2011 Abbott Products Inc.	Feb. 28, 2009 Abbott Products Inc.	Mar. 31, 2011 Abbott Products Inc.	Dec. 31, 2011 Abbott Products Inc.	Dec. 31, 2013 Santarus, Inc. Commercialization Agreement	Dec. 31, 2012 Santarus, Inc. Commercialization Agreement	Dec. 31, 2011 Santarus, Inc. Commercialization Agreement	Aug. 31, 2011 Santarus, Inc. Commercialization Agreement	Jul. 31, 2008 Santarus, Inc. Promotion Agreement	Mar. 31, 2012 Boehringer Ingelheim International GMBH	Dec. 31, 2013 Ironwood Pharmaceuticals, Inc.	May 31, 2012 Ironwood Pharmaceuticals, Inc.	Jul. 31, 2011 Ironwood Pharmaceuticals, Inc.	Oct. 31, 2010 Janssen Pharmaceutica N.V.	Aug. 31, 2010 Janssen Pharmaceutica N.V.	Dec. 31, 2013 Janssen Pharmaceutica N.V.	Mar. 31, 2013 Janssen Pharmaceutica N.V.	Dec. 31, 2013 Janssen Pharmaceutica N.V. Item	Aug. 31, 2012 Janssen Pharmaceuticals, Inc.	Nov. 30, 2008 Mallinckrodt Item	Sep. 30, 2013 Mallinckrodt	Dec. 31, 2008 Mallinckrodt	Dec. 31, 2013 Patheon Puerto Rico, Inc.	Jul. 31, 2005 Valeant Pharmaceuticals International, Inc.	Dec. 31, 2004 Valeant Pharmaceuticals International, Inc.	Dec. 31, 2013 Valeant Pharmaceuticals International, Inc.	Dec. 31, 2012 Valeant Pharmaceuticals International, Inc.	Dec. 31, 2011 Valeant Pharmaceuticals International, Inc.	Dec. 31, 2010 Valeant Pharmaceuticals International, Inc.	May 31, 2002 Valeant Pharmaceuticals International, Inc. 500mg Glumetza	May 31, 2002 Valeant Pharmaceuticals International, Inc. 1000mg Glumetza	Jun. 30, 2013 Ventiv Item	May 31, 2012 Ventiv Item
License and collaborative arrangements
Milestone payment received					$ 48,000,000									$ 2,500,000	$ 500,000	$ 1,000,000		$ 5,000,000
License and other revenue	12,796,000	18,798,000	81,798,000				48,000,000		1,400,000	3,300,000	2,000,000									1,400,000	2,200,000										1,600,000	1,600,000	1,600,000
Upfront fee received						25,000,000							12,000,000				900,000		5,000,000				10,000,000			4,000,000		25,000,000	25,000,000
Revenue recognized				11,300,000				12,600,000
Royalties on net product sales, percentage in 2011									26.50%
Royalties on net product sales, percentage in 2012									29.50%
Royalties on net product sales, percentage in 2013 and 2014									32.00%
Royalties on net product sales, percentage in 2015 and beyond									34.50%
Royalty revenue	45,003,000	44,535,000	9,997,000						42,100,000	42,800,000	9,600,000																			400,000	400,000	400,000
Period during which distribution and sales responsibility of product transitioned											4 months
Percent of out-of-pocket costs reimbursed to company									70.00%
Percent of out-of-pocket costs reimbursed by company									30.00%
Upfront agreement fee deferred revenue balance	15,516,000	18,789,000							3,000,000	4,800,000		9,200,000																		12,500,000
Number of projects completed																						2
Number of products to be developed by utilizing Acuform technology																								4
Aggregate upfront fee received																										5,500,000
Upfront fee received for formulation work to be performed under the agreement																										1,500,000
Milestone revenue recognized																									5,000,000
Non-cancelable purchase orders and minimum purchase obligations																											500,000
Royalty receivable as a percentage of net sales																																		6.00%	1.00%
Royalty payable as a percentage of net sales																																		1.00%
Royalty expense																														400,000	500,000	200,000
Number of part-time sales representatives dedicated to the Company																																				27	78
Monthly fixed fee payment																																				$ 200,000	$ 500,000
Number of full-time sales representatives dedicated to the company																																				2